Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.58 |
| ▸ | RAB9A | P51151 | 7/20 | 0.58 |
| ▸ | CHKA | P35790 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CCR3 | P51677 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31419727 | 0.95 | NPC1 (0.56) | NPC1RAB9ACHKAMAPTL3MBTL1 | |
| SCHEMBL31200478 | 0.92 | NPC1 (0.47) | NPC1RAB9ACHKAMAPTL3MBTL1 | |
| SCHEMBL31389076 | 0.91 | NPC1 (0.62) | NPC1RAB9ACHKAMAPTL3MBTL1 | |
| SCHEMBL25528395 | 0.91 | NPC1 (0.62) | NPC1RAB9ACHKAMAPTL3MBTL1 | |
| SCHEMBL25209406 | 0.91 | NPC1 (0.62) | NPC1RAB9ACHKAMAPTL3MBTL1 | |
| SCHEMBL24071502 | 0.91 | NPC1 (0.62) | NPC1RAB9ACHKAMAPTL3MBTL1 | |
| SCHEMBL31200451 | 0.91 | NPC1 (0.62) | NPC1RAB9ACHKAMAPTL3MBTL1 | |
| SCHEMBL31389071 | 0.91 | NPC1 (0.62) | NPC1RAB9ACHKAMAPTL3MBTL1 | |
| SCHEMBL31419703 | 0.89 | NPC1 (0.61) | NPC1RAB9ACHKAMAPTL3MBTL1 | |
| SCHEMBL24071450 | 0.88 | NPC1 (0.65) | NPC1RAB9ACHKAMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092030-A1 | ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2025-03-20 | — | — | US | disclosed |
| WO-2024233501-A2 | THERAPEUTIC COMPOUNDS | ALLOROCK, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092030-A1 | ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A | PDE2A, GUCY1A1, GCGR | NPC1 1065/4885RAB9A 960/4885CHKA 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.